Introduction
HIV is now considered a chronic, manageable disease. However the lifelong therapy required to control HIV means considerations such as patient quality of life and cost of therapy are becoming increasingly influential in product choice. Consequently the development of new products which offer limited improvements in efficacy but better convenience and tolerability has changed prescription practices

Scope
Analysis of current treatment regimens and unmet needs, based on a survey of 180 physicians in the seven major pharma markets around the world
Current epidemiology of HIV in the seven major markets, including prevalence, age and gender splits, with analysis of diagnosis and chain of care
A detailed examination of the numbers of patients on each line of therapy, which drugs they are taking and for what reasons is provided
An assessment of key unmet needs within HIV and the changes in mortality since the introduction of HAART is included
Highlights
Increasing transmission by heterosexual contact suggests both an absence and/or ineffectiveness of HIV awareness and education programs. It also exposes more females to the HIV virus, leading to unique disease management issues.

The success of HAART in prolonging survival within the HIV population introduces new psychosocial challenges beyond pharmaceutical management. Age-related conditions, comorbidities and the desire to conceive call for a new multi-faceted pattern of patient care

Datamonitor physician research indicates that of 273,000 first-line treated individuals, globally 79% are now receiving fixed dosed combinations (FDCs). While guidelines and HIV specialists have embraced their convenience and simplicity, the unstructured nature of later lines of therapy requires increasing individualization

Reasons to Purchase
Understand the unique disease management issues raised by increasing heterosexual transmission of HIV to females
Identify opportunities for new patterns of patient care following the success of HAART in prolonging survival
Explore unmet needs in HIV therapy, as identified by treating physicians, and including increased individualization in later-line therapy

Introduction
HIV is now considered a chronic, manageable disease. However the lifelong therapy required to control HIV means considerations such as patient quality of life and cost of therapy are becoming increasingly influential in product choice. Consequently the development of new products which offer limited improvements in efficacy but better convenience and tolerability has changed prescription practices

Scope
Analysis of current treatment regimens and unmet needs, based on a survey of 180 physicians in the seven major pharma markets around the world
Current epidemiology of HIV in the seven major markets, including prevalence, age and gender splits, with analysis of diagnosis and chain of care
A detailed examination of the numbers of patients on each line of therapy, which drugs they are taking and for what reasons is provided
An assessment of key unmet needs within HIV and the changes in mortality since the introduction of HAART is included
Highlights
Increasing transmission by heterosexual contact suggests both an absence and/or ineffectiveness of HIV awareness and education programs. It also exposes more females to the HIV virus, leading to unique disease management issues.

The success of HAART in prolonging survival within the HIV population introduces new psychosocial challenges beyond pharmaceutical management. Age-related conditions, comorbidities and the desire to conceive call for a new multi-faceted pattern of patient care

Datamonitor physician research indicates that of 273,000 first-line treated individuals, globally 79% are now receiving fixed dosed combinations (FDCs). While guidelines and HIV specialists have embraced their convenience and simplicity, the unstructured nature of later lines of therapy requires increasing individualization

Reasons to Purchase
Understand the unique disease management issues raised by increasing heterosexual transmission of HIV to females
Identify opportunities for new patterns of patient care following the success of HAART in prolonging survival
Explore unmet needs in HIV therapy, as identified by treating physicians, and including increased individualization in later-line therapy